Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Biomarker Testing topic
No spam. Unsubscribe anytime.
Committee converts biomarker coverage bill into study, orders actuarial analyses and CMS review
Summary
Facing uncertainty about premium impacts, the committee removed a proposed per-member fee and converted S154 into a strike-all study directing DFR and AHS to analyze costs of covering biomarker testing and any Medicaid/CMS approvals needed, with reports due Jan. 15, 2027; the committee voted to advance the study.
The Senate Health & Welfare Committee amended S154, which originally sought to require coverage for biomarker testing, into a study that directs actuarial and Medicaid impact analyses before the Legislature considers a coverage mandate.
Committee members and finance staff stressed the need for a DFR actuarial analysis of premium impacts and for AHS to report on what CMS approvals would be required before Medicaid could cover biomarker testing. A draft overnight inserted a $5 per-member-per-month fee on qualified health plans to secure a finance referral; members discussed and ultimately removed that fee and decided instead to direct DFR and AHS to produce formal analyses.
Sponsors described the issue as important for patients who need ongoing testing for conditions such as cancer or Alzheimer’s, but members also emphasized the risk of raising premiums and the need to understand how many tests would be used and the resulting cost. "We have to know what we're buying in," said a committee member urging the actuarial review.
The committee approved the strike-all amendment (2.1) converting S154 into a study and voted to move the amended item favorably. The Department of Financial Regulation will produce an estimate of potential premium increases and the state's obligations under federal rules for qualified health plans; the Agency of Human Services will analyze CMS approvals and Medicaid cost impacts. Both entities are due to report to the committee by Jan. 15, 2027.
